Current therapeutic paradigm in pediatric atopic dermatitis : Practical guidance from a national expert panel
Copyright © 2018 SEICAP. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION AND OBJECTIVES: Atopic dermatitis (AD) is the most common cutaneous inflammatory disease in both adults and children. Although emerging therapeutic approaches are being investigated for the management of pediatric AD, it still needs to be managed with conventional treatments. This consensus document is aimed at providing an update on general management and therapies of pediatric AD, defining practical recommendations for using both topical and systemic agents.
MATERIAL AND METHODS: A panel of experts consisting of dermatologists and pediatricians were convened in order to define statements, through a Delphi process, standardizing the management of AD in pediatric subjects in a real-world setting.
RESULTS: A set of practical recommendations obtaining an at least 75% agreement was presented.
CONCLUSIONS: This set of practical recommendations represents a simple and fast snapshot on the pediatric use of common anti-AD therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Allergologia et immunopathologia - 47(2019), 2 vom: 06. März, Seite 194-206 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chiricozzi, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 25.06.2019 Date Revised 25.06.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.aller.2018.06.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289041090 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289041090 | ||
| 003 | DE-627 | ||
| 005 | 20231225061659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.aller.2018.06.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0963.xml |
| 035 | |a (DE-627)NLM289041090 | ||
| 035 | |a (NLM)30268381 | ||
| 035 | |a (PII)S0301-0546(18)30119-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chiricozzi, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current therapeutic paradigm in pediatric atopic dermatitis |b Practical guidance from a national expert panel |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.06.2019 | ||
| 500 | |a Date Revised 25.06.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 SEICAP. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION AND OBJECTIVES: Atopic dermatitis (AD) is the most common cutaneous inflammatory disease in both adults and children. Although emerging therapeutic approaches are being investigated for the management of pediatric AD, it still needs to be managed with conventional treatments. This consensus document is aimed at providing an update on general management and therapies of pediatric AD, defining practical recommendations for using both topical and systemic agents | ||
| 520 | |a MATERIAL AND METHODS: A panel of experts consisting of dermatologists and pediatricians were convened in order to define statements, through a Delphi process, standardizing the management of AD in pediatric subjects in a real-world setting | ||
| 520 | |a RESULTS: A set of practical recommendations obtaining an at least 75% agreement was presented | ||
| 520 | |a CONCLUSIONS: This set of practical recommendations represents a simple and fast snapshot on the pediatric use of common anti-AD therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atopic dermatitis | |
| 650 | 4 | |a Atopy | |
| 650 | 4 | |a Management | |
| 650 | 4 | |a Probiotics | |
| 650 | 4 | |a Therapy | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Calcineurin Inhibitors |2 NLM | |
| 650 | 7 | |a Emollients |2 NLM | |
| 700 | 1 | |a Belloni Fortina, A |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, E |e verfasserin |4 aut | |
| 700 | 1 | |a Girolomoni, G |e verfasserin |4 aut | |
| 700 | 1 | |a Neri, I |e verfasserin |4 aut | |
| 700 | 1 | |a Ricci, G |e verfasserin |4 aut | |
| 700 | 1 | |a Romanelli, M |e verfasserin |4 aut | |
| 700 | 1 | |a Peroni, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergologia et immunopathologia |d 1973 |g 47(2019), 2 vom: 06. März, Seite 194-206 |w (DE-627)NLM000045926 |x 1578-1267 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2019 |g number:2 |g day:06 |g month:03 |g pages:194-206 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.aller.2018.06.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2019 |e 2 |b 06 |c 03 |h 194-206 | ||